Skip to main content

Metabolic and bariatric surgery versus incretin-based therapy in adults aged 65 and older with type 2 diabetes: a nationwide comparative analysis of weight loss and cardiometabolic outcomes

In brief

Older adults lost 23% after surgery, versus 7% with incretin therapy

In a nationwide retrospective cohort of 107,280 adults aged 65 or older with obesity and type 2 diabetes, mean one-year weight loss was 23% after metabolic and bariatric surgery versus 6.9% with incretin-based therapy. Surgery was also associated with lower five-year rates of cardiovascular events, kidney and eye complications, and death, but the nonrandomized comparison cannot establish that surgery caused these advantages.

Journal
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery (Q1)
Published
17 October 2026
Study design
Retrospective cohort
Evidence level
Level 3, Low (CEBM 3b)
Authors
Andrew P Gillikin, Emily P Rabinovich, Thomas H Shin
PMID
43057925
DOI
10.1016/j.soard.2026.10.012

Why clinicians should know about it

Abstract

BACKGROUND: Metabolic and bariatric surgery (MBS) and incretin-based therapy (IBT), including glucagon-like peptide-1 receptor agonists, are effective treatments for obesity and type 2 diabetes mellitus (T2DM), but their long-term comparative effectiveness in older adults remains poorly defined. OBJECTIVES: To compare 1-year weight loss and long-term cardiometabolic outcomes in adults aged ≥65 years with T2DM and obesity treated with MBS versus IBT. SETTING: Nationwide multi-institutional cohort from the Epic Cosmos database. METHODS: This retrospective cohort study examined adults aged ≥65 years with T2DM and body mass index ≥35 kg/m2 who underwent MBS or IBT between 2017 and 2023. The primary outcome was 1-year percent total weight loss. Secondary outcomes included 5-year cumulative incidence of major adverse cardiovascular events, nephropathy, retinopathy, all-cause mortality, and 1-year absolute change in hemoglobin A1C. Overlap weighting was used to estimate treatment effects in the population of clinical equipoise. RESULTS: Among 107,280 patients, (2843 MBS; 104,437 IBT), mean 1-year percent total weight loss was 23.0% (95% confidence interval, 22.6%‑23.3%) after MBS and 6.87% (6.57%‑7.13%) after IBT. At 5 years, MBS was associated with lower cumulative incidence of major adverse cardiovascular events (hazard ratio [HR], .84; .74‑.95), nephropathy (HR, .73; .64‑.85), retinopathy (HR, .65; .55‑.77), and mortality (HR, .66; .54‑.80). Mean absolute hemoglobin A1C change at 1 year was -.80% (95% confidence interval, -.88 to .72%) after MBS versus -.54% after IBT (-.58 to .51%). CONCLUSIONS: MBS was associated with substantially greater weight loss and lower long-term cardiometabolic complications than IBT in older adults with T2DM and obesity, supporting its role as an important therapeutic option in appropriately selected patients.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.